Can Epicore BioNetworks Inc.’s Tomorrow be Different? The Stock Declines Again

 Can Epicore BioNetworks Inc.'s Tomorrow be Different? The Stock Declines Again

The stock of Epicore BioNetworks Inc. (CVE:EBN) is a huge mover today! About 21,500 shares traded hands or 118.63% up from the average. Epicore BioNetworks Inc. (CVE:EBN) has risen 6.00% since October 10, 2016 and is uptrending. It has outperformed by 1.22% the S&P500.
The move comes after 8 months negative chart setup for the $14.16 million company. It was reported on Nov, 9 by Barchart.com. We have $0.45 PT which if reached, will make CVE:EBN worth $1.84M less.

More notable recent Epicore BioNetworks Inc. (CVE:EBN) news were published by: Prnewswire.com which released: “Epicore BioNetworks Inc. Reports Results for Fiscal Year 2016” on October 07, 2016, also Prnewswire.com with their article: “Epicore BioNetworks Inc. Reports Second Quarter Results for Fiscal Year 2016” published on February 23, 2016, Globenewswire.com published: “Epicore BioNetworks Inc. Announces New Regional Manager” on November 20, 2014. More interesting news about Epicore BioNetworks Inc. (CVE:EBN) were released by: Seekingalpha.com and their article: “The Secular Demand In The Shrimp Industry Will Benefit Epicore BioNetworks (EPCBF)” published on August 21, 2015 as well as Theglobeandmail.com‘s news article titled: “Investor likes small-caps with dividends, little debt” with publication date: April 11, 2014.

Epicore BioNetworks Inc. develops, makes and markets specialty biotechnology, biochemical and nutrition products. The company has a market cap of $14.16 million. Epicore specialty biochemical products are mixtures of specialty organic, inorganic and biochemical ingredients that facilitate microbe and plant growth. It has a 9.14 P/E ratio. Some Epicore products (such as its EPIZYM-AGP COMPLETE) stimulate algae growth, an important property in shrimp and bivalve hatcheries that grow algae as animal food.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Related posts

Leave a Comment